Leveraging its proprietary technology platforms, Alphamab Oncology has developed a highly differentiated pipeline of novel drug candidates, including single domain antibodies, bispecific antibodies, and BADCs. Envafolimab (KN035), the world's first subcutaneously injected PD-L1 inhibitor, has received market approval, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Four bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines, such as dual-payload ADCs, are advancing rapidly. Two programs were recognized by China’s "New Drug Development" initiative, four products had collectively received five FDA Orphan Drug designations, and three products were granted four Breakthrough Therapy Designations by NMPA.
